Cyclopharm Limited

Cyclopharm Limited (CL) is a medical and health care equipments manufacturing company. The company is engaged in the manufacturing and sales of medical equipment and radiopharmaceuticals with a specialization in the area of lung imaging in the niche market segment of nuclear medicine. The company developed its product under collaborative research program with major teaching hospital and its nuclear physicist. CL business operations are organized in two segments namely Technegas and Molecular Imaging. The Technegas segment is engaged in supplying diagnostic equipments and consumables used by physicians for the detection of pulmonary embolism. CL has installed more than 1,100 technegas systems in hospitals throughout the world and have more than 2.1 million patient studied. The molecular imaging radiopharmaceuticals are used by physicians for detection of cancer, neurological disorders and cardiac disease. Some of the key subsidiaries of the company are Cyclomedica Europe Limited and Cyclomedica Ireland Limited. Geographically, the company has operations in Australia, Asia, Europe, UK, Germany and Canada. Recently, Cyclopharm Limited formed a Joint Venture with Alfred Health Solutions (AHS) to provide medical imaging services to Macquarie University Hospital (MUH). The company is headquartered at Melbourne in Victoria, Australia.